[The efficacy of kurantil and its effect on thrombocytic hemostasis in patients with chronic glomerulonephritis].
The paper treats of the mechanisms of antiaggregant and vasoactive effect of curantyl (C) in chronic glomerulonephritis (ChGN). As many as 85 ChGN C-treated patients were examined; positive treatment effect was seen in 35.5%, negative one in 12.9% of the patients; no effect in 25.8%. It has been ascertained that in some instances prognostically unfavourable forms of ChGN do respond to C treatment. Efficacy of C therapy is predictable from the baseline 24 h proteinuria and decrease in urinary excretion of products of fibrinogen/fibrin degradation during the first week of treatment.
Kolesnyk
M O
MO
Lapchyns'ka
I I
II
Bielyts'ka
H O
HO
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D004176:Dipyridamole / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*
D004176:Dipyridamole